Extravasation of paclitaxel (taxol) clinical course

Onkologie

Volumn 22, Issue 4, 1999, Pages 318-320

  Riedel, U ^b   Serke, Monika ^a   Schonfeld N ^b   Loddenkemper, R ^b  

^a Lungenklinik Heckeshorn   (Germany)

^b NONE

Author keywords

Paclitaxel extravasation; Severe cutaneous and general reaction

Indexed keywords

PACLITAXEL;

AGED; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG EXTRAVASATION; FEVER; HUMAN; HYPERPIGMENTATION; HYPOTENSION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; NEUROPATHY; SCLEROSIS; SKIN MANIFESTATION; THROMBOCYTOPENIA; VERTIGO;

EID: 0032842459     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026965     Document Type: Article

References (24)

1. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff RB, Sorbara L, Zeheb R: Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 1986;466:733-744.
2. McGuire WP, Rowinsky EK, Rosensheim NB, Grumbine FC, Ettinger DS: Taxol: A unique antineo-plastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.
3. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of Taxol, novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
4. Lubejko BG, Sartorius SE: Nursing considerations in paclitaxel (Taxol®) administration. Semin Oncol 1993;20(suppl 3):26-30.
5. Gallina EJ: Practical guide to chemotherapy administration for physicians and oncology nurses; in De Vita Vincent T, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology, 4th ed. Philadelphia, Lippincott, 1993, pp 2570-2580.
6. VanSloten Harwood K, Aisner J: Treatment of chemotherapy extravasation: Current status. Cancer Treat Rep 1984;68:939-945.
7. VanSloten Harwood K, Johnstone Strauman J: Management of chemotherapy tissue extravasation; in Dutcher JP, Wiernik PH (eds): Handbook of Hematologic and Oncologic Emergencies, New York, Plenum Medical Book, 1987, pp 331-341.
8. Bicher A, Levenback C, Burke TW, Morris M, Warner D, DeJesus Y, Gershenson DM: Infusion site soft-tissue injury after paditaxel administration. Cancer 1995;76:116-120.
9. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH: Taxol-induced soft-tissue injury secondary to extravasation: Characterization by histopathology and clinical course. J Natl Cancer Inst 1994;86:51-53.
10. Dorr RT: Antidotes to vesicant chemotherapy extravasation. Blood Rev 1990;4:41-60.
11. Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 1978;61:86-92.
12. Cancer Chemotherapy Guidelines. Recommendations for The Management of Extravasation and Anaphylaxis. Pittsburgh, Oncology Nursing Society, 1988.
13. Dorr RT, Snead K, Liddil LD: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 1996;78:152-156.
14. Bertelli G, Cafferata MA, Ardizzoni A, Gozza A, Rosso R, Dini D: Letter to the article: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 1997;79:2266-2269.
15. Du Bois A, Fehr MK, Bochtler H, Koechli OR: Clinical course and management of paclitaxel extravasation. Oncol Rep 1996;3:973-974.
16. Stein ME, Drumea KD, Abu-Rasmi R, Haim N: Taxol-induced cellulitis after extravasation: a rarely reported event (letter). Am J Clin Oncol 1997; 20:540.
17. Raymond E, Cartier S, Canuel C, Louvet C, Demuynck B, Debray M, Varette C, Baux S, Mimoun M, de Gramont A, Krulik M: Extravasation de paclitaxel (Taxol®). Rev Med Interne 1995;16:141-142.
18. Berghmans T, Klastersky J: Paclitaxel-induced cutaneous toxicity. Support Care Cancer 1995;3:203-204.
19. Meehan JL, Sporn JR: Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation. J Natl Cancer Inst 1994;86:1250-1251.
20. Hidalgo M, Benito J, Colomer R, Paz-Ares L: Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst 1996;88:1320.
21. Eisenhauer EA, Eisenhauer E, ten Bokkel-Huirnik W, Sweneston K: European-Canadian randomized trial of Taxol® in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
22. Herrington JD, Figueroa JA: Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997;17: 163-165.
23. Noone MH, McCabe MS, Denicoff AM, McCarthy Lepore J: Nursing management of the patient receiving Taxol therapy. Natl Cancer Inst Monogr 1993;15:149-154.
24. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, Del Mastro L, Garrone O, Rosso R, Dini D: Topical dimethyl sulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 1995;13:2851-2855.